SCHEMBL20164112

SCHEMBL20164112

CCCCCCCC/C=C\CCCCCCC(C(N)=O)C(C)N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.54
SOAT1 P35610 2/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C19 P33261 2/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
TP53 P04637 1/20 0.54
CYP3A4 P08684 1/20 0.54
KDM4E B2RXH2 2/20 0.50
CNR1 P21554 1/20 0.47
TERT O14746 3/20 0.46
PTPN1 P18031 3/20 0.46
MAPT P10636 2/20 0.46
BLM P54132 2/20 0.46
HSD17B10 Q99714 2/20 0.46
FABP4 P15090 2/20 0.46
PPARG P37231 2/20 0.46
PPARD Q03181 2/20 0.46
PPARA Q07869 2/20 0.46
GMNN O75496 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28914733 1.00 FAAH (0.54) FAAHSOAT1CYP1A2CYP2C19KMT2A
Palmitic Acid SCHEMBL28175506 0.92 PPARG (0.62) FAAHCYP1A2CYP2C19KMT2ACYP3A4
Erucic Acid SCHEMBL28018379 0.92 PPARG (0.62) FAAHCYP1A2CYP2C19KMT2ACYP3A4
Erucic Acid SCHEMBL28018370 0.92 PPARG (0.62) FAAHCYP1A2CYP2C19KMT2ACYP3A4
Erucic Acid SCHEMBL29013366 0.92 PPARG (0.62) FAAHCYP1A2CYP2C19KMT2ACYP3A4
Stearic Acid SCHEMBL28504955 0.92 PPARG (0.62) FAAHCYP1A2CYP2C19KMT2ACYP3A4
SCHEMBL6901656 0.90 SPHK1 (0.53) TP53MAPTPPARD
SCHEMBL6903713 0.90 SPHK1 (0.53) TP53MAPTPPARD
SCHEMBL6903034 0.89 FAAH (0.56) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL28723753 0.87 FAAH (0.54) FAAHSOAT1CYP1A2CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240390411-A1 COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR SEIKAGAKU CORPORATION (JP) 2024-11-28 US disclosed
CN-114948441-A Stretch laminate with beam elastics and shaped nonwoven layers 宝洁公司 2022-08-30 CN disclosed
CN-112218606-B Stretch laminate with beam elastics and shaped nonwoven layers 宝洁公司 2022-05-27 CN disclosed
US-20220133776-A1 COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR SEIKAGAKU CORPORATION (JP) 2022-05-05 US disclosed
US-11253540-B2 Composition including glycosaminoglycan derivative and chemokine receptor activity regulator SEIKAGAKU CORPORATION (JP) 2022-02-22 US disclosed
CN-114025729-A Absorbent article with functionally shaped topsheet and method of manufacture 宝洁公司 2022-02-08 CN disclosed
CN-113950312-A Absorbent article with functionally shaped topsheet and method of manufacture 宝洁公司 2022-01-18 CN disclosed
CN-113786489-A Composition comprising glycosaminoglycan derivative and chemokine receptor activity modulating material 生化学工业株式会社 2021-12-14 CN disclosed
CN-107708707-B Composition comprising glycosaminoglycan derivative and chemokine receptor activity modulating material 生化学工业株式会社 2021-09-07 CN disclosed
CN-112218606-A Stretch laminate with beam elastics and shaped nonwoven layers 宝洁公司 2021-01-12 CN disclosed
US-20180140628-A1 COMPOSITION INCLUDING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR SEIKAGAKU CORPORATION (JP) 2018-05-24 US disclosed
CN-107708707-A Composition comprising glycosaminoglycan derivative and chemokine receptor activity modulating material 生化学工业株式会社 2018-02-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240390411-A1 COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR CCL5, CCL2, CCR5 FAAH 2816/4885SOAT1 3769/4885CYP1A2 4773/4885
US-11253540-B2 Composition including glycosaminoglycan derivative and chemokine receptor activity regulator CCL5, CCL2, ACKR3 FAAH 2809/4885SOAT1 3802/4885CYP1A2 4775/4885
US-20180140628-A1 COMPOSITION INCLUDING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR CCL5, CCL2, ACKR3 FAAH 2809/4885SOAT1 3802/4885CYP1A2 4775/4885
US-20220133776-A1 COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR CCL5, CCL2, ACKR3 FAAH 2921/4885SOAT1 3864/4885CYP1A2 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.